A large single center's clinical experience with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and a baseline fev1 of less than 40 percent predicted

Authors
Category Primary study
JournalAmerican Journal of Respiratory and Critical Care Medicine
Year 2021
This article has no abstract
Epistemonikos ID: 3875a43f0a3ac16beb600ca9b4e8079b04942bda
First added on: Feb 12, 2025